APO RESEARCH · REPORT
Commercializing Biomarkers in Therapeutic and Diagnostic Applications
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Product & engineering
Understand the product.
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
Selected research
Industry Research
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Research Report 2026
Market perspective
A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
Read the full market overview
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.
Report Scope
This report quantifies the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market by Company
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Type
Consumables
Services
Software
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Application
Oncology
Cardiology
Neurology
Other
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Commercializing Biomarkers in Therapeutic and Diagnostic Applications and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Consumables
- Services
- Software
Applications
- Oncology
- Cardiology
- Neurology
- Other
Companies covered
- Roche
- Dako (Agilent Technologies)
- Merck
- BD
- Abbott
- Genesys Biolabs (20/20GeneSystems)
- Affymetrix
- Agendia
- ALMAC
- Arrayit
- Biocartic
- BG Medicine
- KEGG EXPRESSION Database
- Thermo Fisher
- BGI
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Consumables
- 2.2.3 Services
- 2.2.4 Software
- 2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oncology
- 2.3.3 Cardiology
- 2.3.4 Neurology
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Type
- 3.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Type (2021-2026)
- 3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Type (2027-2032)
4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Breakdown Data by Application
- 4.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Application (2021-2026)
- 4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Perspective (2021-2032)
- 5.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Growth Trends by Region
- 5.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Historic Market Size by Region (2021-2026)
- 5.2.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Forecasted Market Size by Region (2027-2032)
- 5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Dynamics
- 5.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
- 5.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers
- 5.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
- 5.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue
- 6.1.1 Global Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players by Revenue (2021-2026)
- 6.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Players (2021-2026)
- 6.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications Head Office and Area Served
- 6.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players, Product Type & Application
- 6.5 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturers Established Date
- 6.6 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021-2032)
- 7.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021-2026)
- 7.4 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021-2032)
- 8.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021-2026)
- 8.4 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021-2032)
- 9.2 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021-2032)
- 10.2 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021-2026)
- 10.4 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size (2021-2032)
- 11.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Dako (Agilent Technologies)
- 12.2.1 Dako (Agilent Technologies) Company Information
- 12.2.2 Dako (Agilent Technologies) Business Overview
- 12.2.3 Dako (Agilent Technologies) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.2.5 Dako (Agilent Technologies) Recent Developments
- 12.3 Merck
- 12.3.1 Merck Company Information
- 12.3.2 Merck Business Overview
- 12.3.3 Merck Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.3.5 Merck Recent Developments
- 12.4 BD
- 12.4.1 BD Company Information
- 12.4.2 BD Business Overview
- 12.4.3 BD Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.4.5 BD Recent Developments
- 12.5 Abbott
- 12.5.1 Abbott Company Information
- 12.5.2 Abbott Business Overview
- 12.5.3 Abbott Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.5.5 Abbott Recent Developments
- 12.6 Genesys Biolabs (20/20GeneSystems)
- 12.6.1 Genesys Biolabs (20/20GeneSystems) Company Information
- 12.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
- 12.6.3 Genesys Biolabs (20/20GeneSystems) Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments
- 12.7 Affymetrix
- 12.7.1 Affymetrix Company Information
- 12.7.2 Affymetrix Business Overview
- 12.7.3 Affymetrix Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.7.5 Affymetrix Recent Developments
- 12.8 Agendia
- 12.8.1 Agendia Company Information
- 12.8.2 Agendia Business Overview
- 12.8.3 Agendia Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.8.5 Agendia Recent Developments
- 12.9 ALMAC
- 12.9.1 ALMAC Company Information
- 12.9.2 ALMAC Business Overview
- 12.9.3 ALMAC Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.9.5 ALMAC Recent Developments
- 12.10 Arrayit
- 12.10.1 Arrayit Company Information
- 12.10.2 Arrayit Business Overview
- 12.10.3 Arrayit Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.10.5 Arrayit Recent Developments
- 12.11 Biocartic
- 12.11.1 Biocartic Company Information
- 12.11.2 Biocartic Business Overview
- 12.11.3 Biocartic Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.11.5 Biocartic Recent Developments
- 12.12 BG Medicine
- 12.12.1 BG Medicine Company Information
- 12.12.2 BG Medicine Business Overview
- 12.12.3 BG Medicine Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.12.5 BG Medicine Recent Developments
- 12.13 KEGG EXPRESSION Database
- 12.13.1 KEGG EXPRESSION Database Company Information
- 12.13.2 KEGG EXPRESSION Database Business Overview
- 12.13.3 KEGG EXPRESSION Database Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.13.5 KEGG EXPRESSION Database Recent Developments
- 12.14 Thermo Fisher
- 12.14.1 Thermo Fisher Company Information
- 12.14.2 Thermo Fisher Business Overview
- 12.14.3 Thermo Fisher Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.14.5 Thermo Fisher Recent Developments
- 12.15 BGI
- 12.15.1 BGI Company Information
- 12.15.2 BGI Business Overview
- 12.15.3 BGI Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business (2021-2026)
- 12.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Portfolio
- 12.15.5 BGI Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst